Mark Cuban’s Cost-Plus Pricing Is Breaking Pharma’s Patent Playbook
Mark Cuban’s cost-plus pricing isn’t just “disrupting” pharma—it’s stress-testing the entire patent playbook.
For decades, the industry’s economics have been built on a simple, powerful sequence: patent protection buys exclusivity; exclusivity funds hi…
Mark Cuban’s Cost-Plus Pricing Is Breaking Pharma’s Patent Playbook Read Post »
